Nutritional Basis for Colonization Resistance by Human Commensal Escherichia coli Strains HS and Nissle 1917 against E. coli O157:H7 in the Mouse Intestine by Rosalie Maltby et al.
Nutritional Basis for Colonization Resistance by Human
Commensal Escherichia coli Strains HS and Nissle 1917
against E. coli O157:H7 in the Mouse Intestine
Rosalie Maltby1, Mary P. Leatham-Jensen2, Terri Gibson1, Paul S. Cohen2, Tyrrell Conway1*
1 Department of Microbiology and Plant Biology, University of Oklahoma, Norman, Oklahoma, United States of America, 2 Department of Cell and Molecular Biology,
University of Rhode Island, Kingston, Rhode Island, United States of America
Abstract
Escherichia coli is a single species consisting of many biotypes, some of which are commensal colonizers of mammals and
others that cause disease. Humans are colonized on average with five commensal biotypes, and it is widely thought that the
commensals serve as a barrier to infection by pathogens. Previous studies showed that a combination of three pre-
colonized commensal E. coli strains prevents colonization of E. coli O157:H7 in a mouse model (Leatham, et al., 2010, Infect
Immun 77: 2876–7886). The commensal biotypes included E. coli HS, which is known to successfully colonize humans at
high doses with no adverse effects, and E. coli Nissle 1917, a human commensal strain that is used in Europe as a
preventative of traveler’s diarrhea. We hypothesized that commensal biotypes could exert colonization resistance by
consuming nutrients needed by E. coli O157:H7 to colonize, thus preventing this first step in infection. Here we report that
to colonize streptomycin-treated mice E. coli HS consumes six of the twelve sugars tested and E. coli Nissle 1917 uses a
complementary yet divergent set of seven sugars to colonize, thus establishing a nutritional basis for the ability of E. coli HS
and Nissle 1917 to occupy distinct niches in the mouse intestine. Together these two commensals use the five sugars
previously determined to be most important for colonization of E. coli EDL933, an O157:H7 strain. As predicted, the two
commensals prevented E. coli EDL933 colonization. The results support a model in which invading pathogenic E. coli must
compete with the gut microbiota to obtain the nutrients needed to colonize and establish infection; accordingly, the
outcome of the challenge is determined by the aggregate capacity of the native microbiota to consume the nutrients
required by the pathogen.
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Introduction
The gastrointestinal (GI) tract is home to a complex microbial
community that has been implicated in both human health and
disease. The GI tract is comparable to a chemostat in that the
contents constantly turn over and to be successful in this highly
competitive environment, an organism must reproduce at least as
fast as the turnover rate or it will fail to colonize [1,2]. Freter noted
several factors that contribute to colonization success, and
concluded that the most important is competition for resources,
which led to the nutrient-niche hypothesis: in order to successfully
colonize in the absence of adhesion to the mucosal surface an
organism must use at least one limiting nutrient better than all
other competitors [1,3,4,5,6].
Collectively, the human gut microbiota consists of 1,000 to
36,000 different species of bacteria [7], although the number in
any one individual is thought to be between 500 and 1,000 species
[8]. The gut microbiota is predominately comprised of anaerobic
bacteria, mostly in the Firmicutes and Bacteriodetes phyla.
Escherichia coli is the predominant facultative anaerobe in the
mammalian GI tract, although other facultatives are present
[9,10]. Recent work from our laboratories suggests that E. coli
exists in a symbiotic relationship with the anaerobic members of
the gut microbiota. Through normal nutrient processing the
anaerobes degrade complex polysaccharides, releasing the mono-
and disaccharides E. coli needs for growth. In return, E. coli helps
create an anaerobic environment by scavenging oxygen [11,12].
This may explain why E. coli and other facultative anaerobes are
the first colonizers of the infant gut [13,14].
Once established, the gut microbiota is very stable, such that
invading organisms often fail to colonize. This barrier effect is
predicted by Freter’s nutrient-niche hypothesis and is termed
colonization resistance (CR) [10]. In a recent review, Stecher and
Hardt explain that while the mechanisms of CR are incompletely
understood, it is thought that they include direct inhibition of
pathogens, the stimulation of host defenses, and nutrient depletion
[15]. However, CR is not always effective, and invading species
are sometimes able to compete with the microbiota, grow to
sufficient numbers for colonization of the intestine, and cause
disease. For example, E. coli pathogens infect humans, despite an
average of 5 commensal strains of E. coli colonizing a human at
any given time [16]. The disease burden of E. coli in the world is
high and mostly carried by children in developing nations, where
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infantile diarrhea is a major factor in childhood mortality and up
to 60% of cases can be attributed to two pathotypes of E. coli [17].
In developed nations, E. coli is not endemic, but disease outbreaks
do occur, with approximately 5,000 cases of Shiga toxin-
producing E. coli infection reported in the United States in 2011
[18]. In addition to enteric infections, disruptions in the gut
microbiota have been indicated in inflammatory bowel disease
[19,20], and overgrowth of certain adherent and invasive E. coli
has been associated with Crohn’s disease [21,22]. It is becoming
increasingly apparent that a better understanding of the role of the
commensal microbiota in CR is needed in order to effectively treat
and prevent disease [23,24].
Previously, we showed that E. coli MG1655, a commensal strain,
and E. coli EDL933, an O157:H7 strain, use different sugars to
colonize the streptomycin-treated mouse intestine [25]. Further-
more, we recently showed incomplete CR amongst different
commensal E. coli strains to E. coli EDL933 invasion in the
streptomycin-treated mouse model [26]. Although pre-coloniza-
tion of individual commensal strains did not prevent colonization
by E. coli EDL933, a combination of three commensal strains was
effective [26]. On the basis of these findings, we hypothesized that
a potential strategy for preventing colonization by enterohemor-
rhagic E. coli would be to pre-colonize mice with a combination of
commensal strains that would fill the sugar-defined nutritional
niches normally available to invading E. coli pathotypes. However,
the sugar-defined niche of only one commensal strain has been
characterized to date (16).
In order for such probiotic measures to be effective, the
nutritional niches of both pathogenic and commensal strains must
first be understood. The three commensal strains found to be the
most effective at filling the nutritional niche of E. coli EDL933, in
combination, were E. coli MG1655 (a K-12 human commensal
strain), E. coli Nissle 1917 (a probiotic strain), and E. coli HS (a
normal human commensal strain) [26]. E. coli Nissle 1917 was first
isolated from an uninfected soldier during an outbreak of Shigella in
1917. The strain has been marketed for treatment of infectious
diarrhea [27], and has shown to be as effective as current
antibiotic treatments for the remission of ulcerative colitis [28]
with no adverse effects reported [29]. E. coli Nissle 1917 lacks
many of the virulence factors of pathogenic strains, but has several
‘‘fitness factors’’, including anti-inflammatory properties, enhance-
ment of host barrier function, and induction of the expression of
human beta-defensins [30]. E. coli HS was first isolated in 1958
from a healthy human volunteer during a study of Shigella flexneri
[31]. It is considered a true human commensal, colonizing humans
strongly (1010 CFU/g feces) with no sign of disease [32]. Its
genome recently was sequenced [33]. E. coli HS has been used
extensively as a non-pathogenic control for human and animal
studies of pathogenic E. coli, although little is known about the
nature of E. coli HS in vitro or in vivo.
Despite its myriad benefits, the safety of E. coli Nissle 1917 as a
probiotic has been questioned. Gronback et al showed that when
both the host gut microbiota and adaptive immunity are defective
in mice, E. coli Nissle 1917 was able to translocate through the
epithelial layer, leading to dissemination, septicemia, and death of
the animals [34]. The authors noted that although patients with
incomplete gut microbiota have been the successful targets for
probiotic treatment, cases have arisen where probiotics were
associated with sepsis and other adverse effects, especially in
immunocompromised patients [35,36,37,38]. Also, when mice
pre-colonized with only E. coli Nissle 1917 are fed a low dose of E.
coli EDL933, the pathogenic strain is able to grow, albeit
marginally, and persist in the intestine for the 11 day duration
of the experiment [26]. Clearly, a greater understanding is needed
of the physiology of commensal E. coli strains, keeping in mind that
any positive effect against colonization of a pathogen may need to
include multiple strains. In this study we determined the sugar-
defined niches of E. coli strains HS and Nissle 1917, and compared
them to those of the previously characterized strains, E. coli
MG1655 and E. coli EDL933.
Results
Generation of sugar-negative strains
To determine which carbon sources are utilized for colonization
by E. coli HS and Nissle 1917, mutants were constructed that were
unable to utilize specific sugars for growth (Table 1). E. coli Nissle
1917 deletions were constructed via Lamda Red allelic replace-
ment, as described previously [39]. Mutation frequency in E. coli
Table 1. Bacterial strains and plasmids used in this study.
Strain or Plasmid Genotype or phenotype1 Reference
HS Wild type [33]
HS StrR Spontaneous StrR mutant of HS This Study
HS StrRNalR Spontaneous NalR mutant of HS StrR This Study
Nissle 1917 StrR Spontaneous StrR mutant of Nissle 1917 [45]
EDL933 StrRRifR Spontaneous RifR mutant of EDL933 StrR [46]
Strains derived from HS StrR:
DaraBAD D(araB-araD)::cat This Study
araBAD+ HS araBAD+ (restored to WT) This Study
DfucK DfucK::kan This Study
DgalK DgalK::cat This Study
galK+ HS galK+ (restored to WT) This Study
DgntK DidnK DgntK DidnK::cat This Study
DlacZ DlacZ::cat This Study
DmanA DmanA::cat This Study
DnagE DnagE::cat This Study
DnanAT DnanAT::cat This Study
DrbsK DrbsK::cat This Study
DuxaC DuxaC::kan This Study
Strains derived from Nissle 1917 StrR:
DagaWEFA D(agaW- agaA)::cat This Study
DaraBAD D (araB-araD)::cat This Study
DfucK DfucK::kan This Study
DgalK DgalK::cat This Study
DgntK DgntK::cat This Study
DlacZ DlacZ::cat This Study
DmanA DmanA::cat This Study
DnagE DnagE::cat This Study
DnanAT DnanAT::cat This Study
DrbsK DrbsK::cat This Study
DuxaC DuxaC::kan This Study
Plasmids:
pKD46 Ts Ampr ParaC-l-red recombinase [39]
pKM208 Ts Ampr lacI Ptac-red-gam-lacI [40]
pCP20 Ts Ampr FLP recombinase [39]
1StrR, streptomycin resistance; NalR, nalidixic acid resistance; RifR, rifampicin
resistance; AmpR, ampicillin resistance; TS, temperature sensitive replication.
doi:10.1371/journal.pone.0053957.t001
Colonization Resistance to E. coli O157:H7
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HS by the routine Datsenko-Wanner method was low, as has been
reported by others for non-K12 E. coli strains [40,41]. We found
an alternative Lambda Red plasmid, pKM208, which previously
was shown to increase recombination efficiency in enterohemor-
rhagic strains of E. coli [40], to be superior for allelic replacement
in E. coli HS.
Confirmation of sugar-negative phenotypes
The goal of this study was to compare the in vivo (i.e., in the
intestine) nutrition of E. coli commensal strains HS and Nissle 1917
with that of the pathogen E. coli EDL933. We previously assessed
the ability of E. coli EDL933 to use 12 different sugars in the
intestine [25]. We note that the hexuronates glucuronate and
galacturonate are considered here to be one sugar because
mutation of the hexuronate catabolism pathway eliminates growth
on both sugars. Of these 12 sugars, neither E. coli HS nor Nissle
1917 have the genes for sucrose catabolism and E. coli HS also
lacks the genes for N-acetylgalactosamine catabolism. Hence,
mutations were constructed in the 11 sugar catabolism pathways
possessed by E. coli Nissle 1917 and 10 pathways in E. coli HS.
All mutant genotypes were sequenced and the phenotypes
confirmed by growth on MOPS minimal media and Biolog assays.
Results of the phenotypic assays for the E. coli HS mutants are
shown in Figure 1. Only one of the E. coli HS mutants showed
significant growth on the sugar targeted for mutation, E. coli HS
DnagE, which lacks the N-acetylglucosamine phosphotransferase
system [42]. This gene was chosen for mutation instead of nagA, as
strains lacking nagA have been shown to accumulate N-
acetylglucosamine-6-phosphate, which is toxic to E. coli [9].
Strains lacking nagE are still able to transport N-acetylglucosamine
Figure 1. Phenotypic assay results for E. coli HS mutants. A–L. Biolog GN2 (Gram negative carbon nutrition) plates were utilized to assess the
overall metabolic capacity of the mutants constructed in E. coli HS to consume 95 individual carbon sources (see Materials and Methods for details).
The kinetic curves plot substrate oxidation vs. time. Green represents carbon source utilization by the E. coli HS wild type strain, red represents the
mutant strain, and yellow represents utilization by both strains. Mutant strains of E. coli HS: (A) DaraBAD, (B) araBAD+, (C) DgalK, (D) galK+, (E) DfucK,
(F) DgntK DidnK, (G) DlacZ, (H) DmanA, (I) DnagE, (J) DnanAT, (K) DrbsK, and (L) DuxaC. M. Sugar utilization was assessed in minimal media
containing 0.2% carbon source. The final O.D.600’s following 12 hour incubations are shown. Note: the generation time of E. coli HS DnagE on N-
acetylglucosamine is 2.6 h compared to 1 h for the wild type (see text for details). The sugars N-acetylneuraminate and ribose are not represented on
the Biolog plate (NA).
doi:10.1371/journal.pone.0053957.g001
Colonization Resistance to E. coli O157:H7
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via the mannose phosphotransferase system, ManXYZ, which has
a broad substrate specificity that includes N-acetylglucosamine
[42]. nagE deficient strains can also access N-acetylglucosamine
through peptidoglycan recycling, although at lower levels [43].
Thus, deletion of nagE does not prevent growth on N-
acetylglucosamine as the sole carbon and energy source, but the
growth rate is significantly lowered. Comparison of growth curves
on MOPS minimal medium with 0.2% N-acetylglucosamine
showed that E. coli HS DnagE had a doubling time of 2.6 h,
compared to 1 h doubling time for the wild type. We also found
that E. coli HS DgntK DidnK retained the ability to grow, albeit
poorly, on gluconate. With gluconate as the sole carbon and
energy source E. coli HS DgntK DidnK reached a final O.D.600 of
0.3 (Figure 1), compared to a final O.D.600 of approximately 1.0
for wild type E. coli HS (data not shown). E. coli HS apparently
possesses an alternative route for gluconate phosphorylation,
despite deletion of the two known gluconate kinase genes [44].
Biolog assays confirmed the sugar-negative phenotypes of the
remaining E. coli HS strains, as shown in Figure 1. Although not
shown, the phenotypes of the E. coli Nissle 1917 mutants were
identical to those of the E. coli HS mutants with the exception of E.
coli Nissle 1917 DgntK, which was unable to grow on gluconate. For
each sugar-negative mutant, Biolog assays indicated the use of
other carbon sources was unaffected (Figure 1).
E coli HS StrR and HS StrR NalR and E. coli Nissle 1917 StrR
and Nissle 1917 StrR NalR are isogenic
To ensure that spontaneous mutations conferring nalidixic acid
resistance do not cause inherent growth defects, equal numbers of
E. coli HS StrR and StrR NalR were competed in the streptomycin-
treated mouse model, as were E. coli Nissle 1917 StrR and StrR
NalR [45], as described previously for E. coli EDL933 [46]. The E.
coli HS StrR and StrR NalR strains co-colonized for 15 days at
approximately 108 CFU/g feces (data not shown) and thus are
considered isogenic and can be regarded as wild type strains.
The in vivo carbon nutrition of E. coli HS
In order to test which carbon sources are important for
intestinal colonization of E. coli HS, sugar-negative mutants were
competed against their wild type parent strain in streptomycin-
treated mice by feeding 105 CFU of both strains. Results for the
initiation phase (Day 1) and maintenance phase (Day 9), which
best reflects the outcome of competition following initiation of
colonization [9], are shown in Table 2. Representative plots of
mutations causing no colonization defect, or causing moderate or
severe defects are shown in Figure 2. For 6 of the 10 sugars tested,
the mutation was shown to cause a statistically significant defect of
the mutants compared to the wild type during the maintenance
stage of colonization. The relative severity of the colonization
defects of the E. coli HS mutants was galactose.arabinose.
gluconate.N-acetylglucosamine.lactose.ribose. N-acetylneura-
minate, fucose, mannose, and hexuronates were found to be
unnecessary for growth of E. coli HS in the intestine.
Colonization defects are due to deletion of the targeted
gene
To ensure that inability to co-colonize with the wild type parent
was in fact due to the genetic disruption of the specific sugar
utilization pathway and not a deleterious mutation at an
unintended second site, complemented strains were constructed.
To save mice, only two mutations were complemented. Previously,
we found that complementation restored the wild type phenotype
and eliminated the colonization defect, confirming that the defect
was caused by the mutation and not a second site mutation [47].
In this study, E. coli HS DaraBAD (arabinose negative) and E. coli
HS DgalK (galactose negative) were chosen for restoration of gene
function because they showed the greatest defects when colonized
against the wild type strain, a 2.5 and 3.1 log difference,
respectively (Table 2). When these functions were restored by
reintroduction of the wild type alleles, the complimented strains
showed restoration of sugar utilization in Biolog assay (Figure 1),
and no colonization defect in competition with the wild type
(Table 2).
The in vivo carbon nutrition of E. coli Nissle 1917
Analogous to the experiments described above for E. coli HS, a
series of metabolism mutants was competed against the wild type
E. coli Nissle 1917 parent strain (StrR NalR). The results for
initiation (Day 1) and maintenance (Day 9) phases in competitive
colonizations are shown in Table 3. Representative plots of three
colonization experiments are shown in Figure 3. For 7 of the 11
sugars tested, mutation was shown to cause a statistically
significant defect in the maintenance stage of colonization. The
relative severity of the colonization defects of the E. coli Nissle 1917
strains was arabinose.fucose.galactose.gluconate.N-acetylga-
lactosamine.mannose = N-acetylneuraminate. Of the sugars test-
ed, only lactose, N-acetylglucosamine, the hexuronates, and ribose
were found to be unnecessary for growth of E. coli Nissle 1917 in
the intestine.
E. coli strains HS, Nissle 1917, MG1655, and EDL933
display different nutritional profiles in streptomycin-
treated mice
Previously we demonstrated that E. coli MG1655 and E. coli
EDL933 display different nutritional profiles in the streptomycin-
treated mouse intestine (16). Table 4 compares the in vivo carbon
preferences of four E. coli strains: E. coli MG1655, the K12 strain;
the enterohemorrhagic O157:H7 type strain E. coli EDL933; E.
coli Nissle 1917; and E. coli HS. Of the 12 sugars tested, E. coli
EDL933 uses seven of them, in order of preference, ribose.ga-
Table 2. E. coli HS sugar utilization in the mouse intestine.
Log10 difference on:
Mutation Day 1 Day 9 p Value
DaraBAD 0.860.4 2.560.4 2.6161024
araBAD+ 0.060.6 0.760.6 5.561021
DfucK 0.460.3 0.060.4 9.161021
DgalK 0.460.4 3.160.7 1.1361023
galK+ 0.560.1 0.460.1 3.561022
DgntK DidnK 1.160.4 2.460.4 2.0661025
DlacZ 0.460.7 1.060.5 4.5661022
DmanA 0.660.2 0.360.3 7.0561021
DnagE 0.460.4 1.960.4 8.4261025
DnanAT 0.860.5 1.360.7 7.6261022
DrbsK 0.360.5 0.860.4 1.7861022
DuxaC 0.060.4 0.160.6 8.4561021
The difference between population density of the wild type and each mutant
strain is shown at Day 1 and Day 9, plus or minus the standard error of the
mean. Significant values (bold) indicate log difference .0.8 and student’s t test
value P,0.05 at Day 9.
doi:10.1371/journal.pone.0053957.t002
Colonization Resistance to E. coli O157:H7
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lactose.sucrose.mannose.N-acetylglucosamine.arabinose.
hexuronates (16). Therefore, E. coli EDL933 is able to use 2
sugars that are not used by the commensals: sucrose, which
cannot be catabolized by the commensals because they lack the
pathway, and the hexuronates, the loss of which has the least
impact on colonization by E. coli EDL933. The results in Table 4
show that each strain displays a unique nutritional program in
the streptomycin-treated mouse intestine.
E. coli HS and Nissle 1917 fill the sugar-defined niches
occupied by EDL933
Previously we showed that pre-colonization with three com-
mensal strains for 10 days was sufficient to prevent subsequent
challenge by E. coli EDL933, which was completely eliminated
from the intestine [26]. If the basis for exclusion of E. coli EDL933
in that experiment was because the commensals utilized the
nutrients needed by E. coli EDL933 to compete and colonize, we
reasoned that any commensal strain or combination of strains that
effectively catabolizes the sugars used by E. coli EDL933 would
prevent its colonization. Therefore, we tested the ability of E. coli
EDL933 to colonize mice that were pre-colonized with E. coli HS
and E. coli Nissle 1917, which the data in Table 4 indicated should
be equally effective without MG1655 present. The two commensal
strains were fed to mice at the beginning of the experiment, using
nalidixic acid selection to enumerate E. coli HS StrRNalR and
chloramphenicol selection to enumerate E. coli Nissle 1917
DlacZ::cat (as shown in Table 3 and Figure 3, the lacZ mutation
does not affect its colonization). The precolonized animals were
challenged on day 10 with E. coli EDL933 StrRRifR and the
experiment was continued for 11 more days. The results of this
experiment, shown in Figure 4, indicated that pre-colonization for
10 days with the two commensal E. coli strains did indeed
completely prevent challenge by E. coli EDL933, which was
eliminated 5 days following association. Thus, some but not all
commensal E. coli strains exert CR against E. coli EDL933 in the
mouse intestine.
Discussion
The results from this study show that the human commensals E.
coli HS and E. coli Nissle 1917 each occupy a unique nutritional
niche in the mouse intestine (Table 4). Of the 12 sugars available
in the mucus layer, E. coli HS has the genetic capacity to use 10
and actually utilizes 6 for colonization: galactose, arabinose,
gluconate, N-acetylglucosamine, lactose, and ribose. Here, we also
show that E. coli Nissle 1917 uses a differing list of 7 carbon sources
to support colonization, including arabinose, fucose, galactose,
gluconate, N-acetylglucosamine, and N-acetylneuraminate, and
mannose. Previously we showed that E. coli MG1655 utilizes 5
sugars, arabinose, fucose, gluconate, N-acetylglucosamine, and N-
acetylneuraminate [25]. Each of these commensals is capable of
colonizing mice that were pre-colonized with one of the others
[26], and each strain is capable of utilizing at least one sugar not
used by the others in vivo, which suggests that differences in their
in vivo sugar preferences allows them to occupy distinct nutrient-
defined niches in the intestine.
The intestinal niche occupied by pathogenic E. coli EDL933 is at
least partially defined by utilization of arabinose, galactose,
Figure 2. Competitive colonization of E. coli HS mutants vs. wild
type. Sets of three mice were fed 105 CFU of both the E. coli HS wild
type strain and mutant strain. At the times indicated, fecal samples
were homogenized, diluted, and plated as described in Material and
Methods. Compiled data from at least two distinct experiments (6 mice)
are shown. Standard errors of the log10 means of CFU/gram feces are
indicated with error bars. (A) DuxaC, which does not have a
colonization defect; (B) DrbsK, which has a moderate colonization
defect; (C) DgalK, which has a severe colonization defect.
doi:10.1371/journal.pone.0053957.g002
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hexuronates, mannose, N-acetylglucosamine, ribose, and sucrose
for colonization [25]. Together, E. coli HS and E. coli Nissle 1917
utilize all but two of these carbon sources. E. coli HS was found to
be the only strain, besides E. coli EDL933, which uses N-
acetylglucosamine for colonization, whereas E. coli Nissle 1917 was
found to be the only strain, besides E. coli EDL933, to use mannose
(Table 4). Two sugars utilized by the pathogenic E. coli EDL933
but not utilized by the commensal strains tested are sucrose and
the hexuronates. Only E. coli EDL933 has the genes necessary for
sucrose catabolism. It is possible that E. coli EDL933 uses these
sugars in order to initiate colonization, although the energy yield
may not be enough to enable it to persist [25]. Leatham, et al.,
showed that when mice pre-colonized with three commensal E. coli
strains were fed E. coli EDL933, it dropped from a population of
about 105 CFU/g feces to approximately 102 CFU/g feces by
48 hours, and down to ,10 CFU/g feces 10 days post association
[26]. However, individually none of these commensal strains could
prevent colonization of EDL933 [26]. Since the in vivo substrate
range of E. coli Nissle 1917 and HS cover the same sugars without
MG1655 in the mix, we predicted that the two strains would
prevent EDL933 and found indeed this was the case (Figure 4).
This result supports the hypothesis that nutrient consumption by
certain E. coli strains can limit nutrient availability to other E. coli
strains, supporting the idea that CR can be attributed, at least in
part, to competition for nutrients.
It was important in this study to establish that the observed
colonization defects are due to the loss of gene function for sugar
utilization, and not due to second site mutations. Our results
showed that the two mutations that caused the largest colonization
defects in E. coli HS prevented growth on arabinose and galactose,
respectively. Genetic complementation of these mutations (wild
type araBAD was recombined into E. coli HS DaraBAD and wild
type galK into E. coli HS DgalK) restored both complemented
strains to the wild type colonization phenotype (Table 2), proving
that the mutant colonization defects were due solely to mutation of
the specific sugar pathway.
Figure 3. Competitive colonization of E. coli Nissle 1917
mutants vs. wild type. Data were collected as described in Figure 2.
(A) DlacZ, which does not have a colonization defect; (B) DfucK, which
has a moderate colonization defect; (C) DaraBAD, which has a severe
colonization defect.
doi:10.1371/journal.pone.0053957.g003
Table 3. E. coli Nissle 1917 sugar utilization in the mouse
intestine.
Log10 difference on:
Mutation Day 1 Day 9 p Value
DagaWEFA 0.160.1 1.060.2 9.6461023
DaraBAD 0.560.4 2.760.3 1.0161023
DfucK 0.160.1 1.360.1 2.3361029
DgalK 1.060.2 1.260.2 2.7461023
DgntK 0.660.2 1.160.2 4.2861023
DlacZ 0.460.2 0.660.2 7.8561022
DmanA 0.460.2 0.960.3 3.9761022
DnagE 0.060.3 0.060.2 8.776101
DnanAT 0.360.1 0.960.1 3.4561023
DrbsK 20.160.1 0.260.1 1.0661021
DuxaC2 20.9602 20.660.1 4.9261022
The difference between population density of the wild type and each mutant
strain is shown at Day 1 and Day 9, plus or minus the standard error of the
mean. Significant values (bold) indicate log difference .0.8 and student’s t test
value P,0.05 at Day 9.
2Significance refers to Nissle 1917DuxaC ability to outcompete wildtype.
doi:10.1371/journal.pone.0053957.t003
Colonization Resistance to E. coli O157:H7
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It is interesting that E. coli HS is the only E. coli strain found thus
far to utilize lactose for colonization. This strain has often been
used as a control during human and animal studies of pathogenic
E. coli and Salmonella strains due to its ability to consistently
colonize the intestine in high numbers [32,48,49,50]. While
further studies are needed, perhaps utilization of lactose is the
reason for such strong colonization shown by E. coli HS. The
amount of lactose present in the human large intestine differs from
person to person, based on their diet and the presence or absence
of lactase, the enzyme that degrades lactose [51]. It is well known
that humans with decreased lactase production suffer from
gastrointestinal symptoms such as bloating, gas, and diarrhea
when excess lactose passes from the small intestine and is
fermented by members of the gut microbiota [51]. Human adults
are unique among mammals in having the ability to produce
lactase, which most mammals lose upon weaning [52]. The results
of this study suggest that E. coli HS can compete with the native
gut microbiota for lactose.
The use of streptomycin treatment to remove native E. coli from
the mice is required to overcome CR to experimentally introduced
E. coli [10]. It is not possible to conduct the experiments in
conventional mice, which are resistant to colonization by E. coli,
nor would the experiments be possible in humans, who are
colonized on average by five different commensal E. coli strains
[16]. However, with the native E. coli removed by streptomycin
treatment, the system allows the determination of in vivo nutrient
utilization by introduced E. coli strains. Despite alterations to the
mouse microbiota caused by streptomycin treatment, there
remains a large and diverse anaerobe population in the intestine
[10,47]. We contend that results of the experiments described here
extend to a more complex native microbiota found in conven-
tional animals, including humans, and that the aggregate capacity
of the microbiota to consume nutrients needed by invading
bacteria to colonize is a component of CR, which is central to the
probiotic concept [53].
Probiotics are defined as ‘‘live microorganisms which, when
administered in adequate amounts, confer a health benefit on the
host’’ [53]. In recent years, interest in their use to promote human
health has increased dramatically. For almost a century, E. coli
Nissle 1917 has been used as a probiotic for the treatment of
infectious diarrhea [27]. In addition to its ability to occupy a
different nutritional niche from that of E. coli EDL933, E. coli
Nissle 1917 also has several fitness factors [30]. Nissle 1917 is also
effective in maintaining remission in ulcerative colitis patients as
traditional treatments [28,29,54], possibly through the increased
production of indole [55]. However, Leatham, et al., showed that
in the streptomycin-treated mouse model, pre-colonization with E.
coli Nissle 1917 alone was insufficient to keep E. coli EDL933 from
initiating colonization and persisting, albeit in low numbers [26].
Table 4. Sugar utilization in the intestine by E. coli strains.
Sugar-negative phenotype Mutation MG16553 EDL 9333 Nissle 19174 HS4
Arabinose DaraBAD Yes Yes Yes Yes
Fucose DfucK No No Yes No
Galactose DgalK No Yes Yes Yes
Gluconate DgntK DidnK Yes No Yes Yes
Hexuronates DuxaC No Yes No No
Lactose DlacZ No No No Yes
Mannose DmanA No Yes Yes No
N-acetylglucosamine DnagE Yes Yes No Yes
N-acetylgalactosamine DagaWEFA NA5 No Yes NA
N-acetylneuraminate DnanAT Yes No Yes No
Ribose DrbsK No Yes No Yes
Sucrose DsacH NA Yes NA NA
Results show the difference in population sizes of wild type verses mutant strains at Day 9. Yes indicates .0.8 log10 colonization difference and P,0.05.
3Data from [25]. Fabich AJ, Jones SA, Chowdhury FZ, Cernosek A, Anderson A, et al. (2008) Comparison of carbon nutrition for pathogenic and commensal Escherichia
coli strains in the mouse intestine. Infection and immunity 76: 1143–1152.
4This study.
5NA indicates that the pathway is not intact in this genetic background.
doi:10.1371/journal.pone.0053957.t004
Figure 4. Mice precolonized with E. coli HS and E. coli Nissle
1917 prevent colonization by E. coli EDL 933. Mice were fed
105 CFU of E. coli HS StrRNalR and E. coli Nissle 1917 StrR DlacZ::cat. Ten
days later, mice were fed 105 CFU E. coli EDL933. Data were collected as
described in Figure 2.
doi:10.1371/journal.pone.0053957.g004
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This level of colonization may be high enough for E. coli EDL933
to reach the epithelium and express virulence factors. There has
been no work, to date, to indicate that E. coli HS benefits humans.
However, the strain has no adverse effects when fed to humans at
high doses (1010 CFU) and has been used extensively as a
representative of a ‘‘normal’’ commensal strain in human studies,
with no ill outcomes [32,48,49,50]. The new finding reported
here, that E. coli Nissle 1917 and HS prevent colonization by
EDL933, supports the hypothesis that nutrient consumption by
commensal E. coli can limit nutrient availability to pathogens,
which in turn points to the potential of probiotics for preventing
disease.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. E. coli HS was obtained from David Rasko at the
University of Maryland [33]. Derivation of the E. coli Nissle 1917
parent strains used in this study was described previously [45]. The
E. coli EDL933 parent strain used in this study also was described
previously [46]. Cultures were grown on Luria-Bertani (LB) broth
at 250 RPM gyratory shaking or on LB agar. All cultures were
incubated at 37uC, except those containing temperature-sensitive
replicon plasmids, which were grown at 30uC. Antibiotics were
supplemented as required to the following final concentrations:
streptomycin, 100 mg/ml, nalidixic acid, 50 mg/ml, chloramphen-
icol, 30 mg/ml, kanamycin, 40 mg/ml, amplicillin, 100 mg/ml,
rifampicin, 50 mg/ml.
Electroporation and gene replacement
Null alleles were constructed in E. coli Nissle 1917 by using the
Lambda Red allelic replacement system, first described by
Datsenko and Wanner [39]. In our hands, successful allelic
replacement in E. coli HS by the Datsenko and Wanner approach
was rare, so instead we used the approach of Murphy and
Campellone [40], modified as follows. To increase recombination
efficiency, null alleles previously constructed in E. coli MG1655
[25] were used as a template for creating deletions in E. coli HS,
which was possible because their genomes are highly conserved.
The null alleles containing antibiotic resistance cassettes were PCR
amplified from the genome of the appropriate E. coli MG1655
mutant, together with 500 to 700 base pairs of upstream and
downstream flanking sequences, which increases recombination
efficiency [41]. The PCR amplicons were purified using Qiagen
PCR purification kit and electroporated into competent E. coli HS
cells containing the Lambda Red pKM208 plasmid, according to
the Murphy protocol [40]. Cells were recovered in super optimal
broth (SOB) medium at 37uC with shaking for two hours and then
plated on LB agar containing appropriate antibiotics. In this way
the target genes on the E. coli HS genome were deleted and
replaced with chloramphenicol or kanamycin resistance cassettes,
which acted as selectable markers in colonization experiments.
Single gene deletions began with deletion of the start codon and
ended with the stop codon. Deletions of contiguous genes within
an operon began with the start codon of the first gene and ended
with the stop codon of the last gene deleted. Strains with multiple
mutations at different loci were created by sequential allelic
replacement. The first gene was replaced with a resistance cassette,
which was removed using FLP recombinase [39]. The second gene
was then replaced with a resistance cassette, leaving the selectable
marker in place of the second gene deleted. All constructions were
verified by DNA sequencing and phenotypic analysis.
Phenotypic analysis
For confirmation of phenotypes, putative mutant strains and
their wild type parents were grown in 3-N-morpholino propane-
sulfonic acid (MOPS) defined minimal medium [56] with 0.2%
carbon source at 37uC with gyratory shaking for 12–14 hours. Cell
growth was determined spectrophotometrically at OD600. To
demonstrate the slower growth phenotype of the E. coli HS DnagE
mutant, the growth rates in MOPS minimal medium plus 0.2% N-
acetylglucosamine were measured for the mutant and the wild
type. In addition, Biolog assays were used to determine the
metabolic capacity of each deletion strain in E. coli HS, as
described previously [57]. Biolog GN2 (Gram negative carbon
nutrition) plates were used according to manufacturer’s instruc-
tions. In brief, strains were grown overnight on tryptic soy agar,
suspended in Biolog inoculating fluid (gellan gum, 0.2 g/liter;
NaCL, 4.0 g/liter; Pluronic F-68, 0.3 g/liter; 2.5 mM thioglyco-
late) to a final OD600 of 0.2 to 0.3. Each well of the Biolog GN2
plate was inoculated with 150 ml cell suspension and incubated at
37uC for 24 hours in an Omnilog system. Tetrazolium violet dye
reduction was measured at 15 min intervals and plotted vs. time,
resulting in a kinetic curve. The area under the curve served as a
measure of oxidation of each carbon source.
Mouse colonization experiments
The streptomycin-treated mouse model was used to investigate
the in vivo carbon nutrition of E. coli HS and Nissle 1917. This
strategy for the study of intestinal colonization has been used
extensively by our group [9,11,12,25,26,45,46,57,58]. Briefly,
streptomycin treated water (5 g/L) was given to three male, six
week old, CD-1 mice for 24 hours, clearing the intestine of native
facultative anaerobic bacteria [10]. Streptomycin is an aminogly-
coside antibiotic that inhibits protein synthesis, affecting terminal
respiration pathways, carbohydrate metabolism, and cell division
[59,60,61]. Anaerobic bacteria apparently do not take up
aminoglycosides, making them intrinsically resistant [62]. Strep-
tomycin is taken up by actively respiring cells and therefore
selectively removes facultative anaerobic bacteria in the gut
[63,64]. Thus, streptomycin treatment opens a niche for the
colonization of experimentally introduced E. coli strains while
leaving the general population of anaerobic bacteria essentially
intact [10]. Recent work from our laboratory using 16S rRNA
gene sequencing showed that, while streptomycin treatment alters
the anaerobic gut microbiota, the resulting microbial community
is highly diverse, more so than any other animal model currently
available [47].
As described previously [9,11,12,25,26,45,46,57,58], seed cul-
tures were grown in LB liquid medium for eighteen hours prior to
association. Food and water were withheld from the mice for
fourteen hours prior to association. Mice were placed into separate
cages and given 1 ml of a bacterial suspension prepared in 20%
sucrose containing approximately 105 CFU of each strain. Mice
took up the inoculum orally, after which food and streptomycin
treated water were returned ad libidum for the remainder of the
experiment. At 5 and 24 hours post association and every other
day thereafter, 1 gram of feces was diluted in 10 ml of 1%
tryptone, homogenized, serially diluted, and plated onto Mac-
Conkey agar supplemented with appropriate antibiotics (typically
streptomycin and nalidixic acid for wild type strain and
streptomycin and chloramphenicol or kanamycin for mutant
strains). The limit of detection was 101 CFU/g feces. For
experiments in which the challenge strain was associated with
the mice on day 10, food and water again are withheld for 14 h
and then 105 CFU of the challenge strain was fed as described
above, at which time food and water were returned. When
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necessary to differentiate strains, 100 colonies were tooth-picked
from MacConkey streptomycin plates to MacConkey streptomy-
cin and nalidixic acid plates. Colonizations were replicated at least
twice, and the average population sizes and standard error of the
mean of six or more animals was calculated.
Gene complementation
To prove that selected colonization defects were in fact due to
the targeted gene and not inadvertent second site mutations, the
mutations were complemented in E. coli HS. Lambda Red plasmid
pKM208 was electroporated into the mutated strain of choice, and
a gene fragment containing the deleted allele was electroporated
into competent cells as described above. Complemented strains
were rescued by plating on MOPS minimal agar containing 0.2%
of the appropriate carbon source. Strains were then verified via
phenotypic and Biolog analysis, as described above. Compliment-
ed strains (streptomycin resistant) were colonized in the strepto-
mycin-treated mouse model as above against the wild type strain
(streptomycin and nalidixic acid resistant). Fecal samples were
plated onto MacConkey agar supplemented with streptomycin. To
distinguish the complemented strains from the wild type, 100
colonies were tooth-picked from the streptomycin plate to
MacConkey agar containing streptomycin and nalidixic acid.
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